The platelet inhibitor ticagrelor is strongly recommended during 12 months post-acute coronary syndrome (ACS) in European guidelines. We analysed clinical characteristics of patients given ticagrelor for ACS in the real world.
Introduction
Ticagrelor was approved for use in ACS at the end of 2010 by the European Medicines Agency based on the PLATelet inhibition and patient Outcomes (PLATO) trial, which found a reduction in thrombotic events including vascular death when compared with clopidogrel but a higher risk of non-coronary artery bypass grafting (CABG)-related major bleeding when compared with clopidogrel. 1 Ticagrelor has faster onset and achieves more potent platelet inhibition than clopidogrel, 2 and it has been given a strong recommendation in European Society of Cardiology (ESC) guidelines for ST-elevation myocardial infarction (STEMI), 3 non-STEMI (NSTEMI), 4 and myocardial revascularization. 5 Co-prescription of ticagrelor with aspirin post-ACS is recommended for 12 months based on the intended treatment duration in PLATO. The duration of DAPT is likely to be important as early discontinuation of antiplatelet therapy is associated with stent thrombosis and death. 6, 7 We, therefore, wished to characterize a real-world population of patients with ACS that are discharged on ticagrelor in terms of comorbid state, concomitant treatments and management, as well as intended duration of ticagrelor therapy at discharge.
Methods Databases and patient selection
Patients were identified in the nationwide Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry, a full description of which is available elsewhere. 8, 9 In brief, patients admitted to a cardiac unit or other specialized medical facility in Sweden with symptoms suggestive of an acute coronary syndrome (ACS) are included, as are all patients undergoing elective cardiac angiography and/or percutaneous coronary intervention (PCI). Medicines administered prior to or during angiography and PCI are recorded as are medicines administered on discharge including the intended duration of ticagrelor and other antiplatelet agents. SWEDEHEART admission data are recorded on admission, whereas information on treatment given and events during the admission is acquired at discharge. Data accuracy is ascertained via continuous audit of registry entries against source documents, and agreement is 96%. 8 The present study was performed in two different study populations. The first comprised ACS cases surviving until discharge and included patients (i) admitted between 1 January 2012 and 31 December 2013 as recorded in SWEDEHEART (ii) for a diagnosis of ACS (ICD code I21) who were (iii) aged ≥ 18 years and (iv) survived until hospital discharge. We excluded patients who underwent CABG during the index admission. The second study population comprised ACS cases treated with PCI and included patients (i) admitted between 1 January 2012 and 31 December 2013 as recorded in SWEDEHEART (ii) for a diagnosis of ACS (ICD code I21) who were (iii) aged ≥18 years and (iv) underwent PCI during the index admission. We excluded subsequent re-admissions. After the publication of PLATO in 2009, ticagrelor received market authorization by the European Medicines Agency on 3 December 2010.
Data on baseline characteristics were enriched by incorporating information from the Swedish National Patient Registry, which contains data on all diagnoses made during hospital admissions since 1987. The study protocol was approved by the regional ethics committee in Stockholm, Sweden, and the requirement for written consent was waived. Swedish laws regulating clinical quality registries require hospitals to inform patients on admission of their participation and that they are allowed to opt out. The National Board of Health and Welfare approved the merging of registries.
Risk calculations
Risk of in-hospital major bleeding was estimated based on Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) score, 10 -13 and risk of death was estimated based on the Global Registry of Acute Coronary Events (GRACE) score as described elsewhere (refer to Supplementary material online, Appendix S1).
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Statistical analyses
Patients surviving until discharge were stratified based on whether ticagrelor was prescribed at discharge. Patients undergoing PCI were stratified based on whether ticagrelor was prescribed in association with PCI . (prior to or during PCI) irrespective of whether they were subsequently discharged on ticagrelor.
Comparisons between patients treated with ticagrelor and others were performed using Wilcoxon's test for numerical variables or x 2 test for categorical. Multivariable analysis with logistic regression was performed to analyse independent factors associated with discharging patients on ticagrelor. Variables selected for inclusion into the model were age, sex, ACS type (STEMI vs. NSTEMI), Killip class .1 on admission, atrial fibrillation on admission, history of congestive heart failure, renal function, past history of diabetes mellitus, hypertension, myocardial infarction (MI), ischaemic stroke, peripheral vascular disease, significant bleeding history (intracranial, any bleeding leading to previous admission), chronic obstructive airway disease, cancer in last 3 years, characteristics of the admitting hospital including PCI capability and university affiliation, and year of admission.
Estimated glomerular filtration rate was calculated from creatinine using Chronic Kidney Disease Epidemiology Collaboration equation. 17 Continuous variables are shown as mean + standard deviation or median (interquartile range) as appropriate. Categorical variables are shown as count (percentage). All analyses were performed using R version 3.2.0.
Results
The final study population of patients discharged alive post-ACS comprised 28 639 of whom 12 601 (44.0%) were discharged on ticagrelor. The proportion of patients discharged on ticagrelor increased from 33.9% in 2012 to 55% in 2013. Uptake was especially fast in patients undergoing PCI and in particular for STEMI cases as shown in Figure 1 .
Patients discharged on ticagrelor differed significantly from others both in terms of basic characteristics at time of admission ( Table 1 ) and in terms of in-hospital course ( Table 2 ). The ticagrelor population was younger, and a higher proportion had STEMI. Fewer ticagrelor patients had diabetes and hypertension, and fewer had a history of MI, CABG, ischaemic stroke, and bleeding. Among 271 patients discharged on both ticagrelor and anticoagulation, 169 were co-prescribed aspirin, i.e. triple therapy (63.3%) and PCI had been done in 252 patients (93.0%). A higher proportion of patients discharged on ticagrelor were taking b-blockers, angiotensinconverting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB) and statins. The intended duration of ticagrelor therapy in patients discharged alive was 12 months in 82.5% of patients, ,12 months in 9.3%, permanent in 3.8%, and not yet determined at discharge in 4.3%.
A higher proportion of ticagrelor patients were treated at a university hospital and at a hospital capable of offering PCI. The proportion of ticagrelor patients who underwent PCI during their admission was accordingly high. A. Sahlén et al. Table S1 ). A total of 11 640 patients (57.8%) were administered ticagrelor prior to or during PCI, of whom 9610 (82.6%) were subsequently also discharged on ticagrelor, while 1397 were discharged on clopidogrel (12.0%) and 471 were not discharged on DAPT at all (4.0%; Supplementary material online, Table S2 ). As shown in Figure 2 , the increasing trend to managing PCI patients with ticagrelor was largely driven by more patients being commenced on ticagrelor prior to PCI. Independent factors associated with discharging patients on ticagrelor are shown in Table 3 . After adjusting for age and sex, there was no association between discharge on ticagrelor and atherosclerotic risk factors such as diabetes mellitus, hypertension, and impaired renal function, and there was an inverse association with having established atherosclerosis (MI, ischaemic stroke, and peripheral vascular disease).
Risk scores are shown in Table 4 for patients discharged alive on ticagrelor vs. not on ticagrelor. Patients discharged on ticagrelor had lower GRACE score, the median score being in the low risk range when compared with non-ticagrelor patients for whom the median was in the intermediate risk range. In the case of CRUSADE risk scores, there was a statistical difference indicating that ticagrelor patients had significantly lower CRUSADE bleeding risk score, but the difference was numerically modest and the subgroup medians were both in the low risk range.
Discussion
The present study was designed to evaluate the factors associated with being administered ticagrelor in a real-world population of patients admitted for ACS in Sweden. The first finding was that adoption of ticagrelor in ACS was very rapid after its introduction, especially in cases managed by PCI and in STEMI cases in particular. Secondly, the population discharged on ticagrelor constituted a lower-risk population than others, the latter group being a subset of patients characterized by higher risk and predominantly discharged on clopidogrel. Thirdly, at variance with the protocol used in PLATO, ticagrelor was in fact co-prescribed with an oral anticoagulant in a significant minority of cases (2.1%) and only 82.5% of patients were a priori intended for 12 months of DAPT at the time of discharge.
The present study demonstrates that adoption of ticagrelor in management of ACS in Sweden was very rapid after the incorporation of the PLATO trial results into the ESC guidelines for NSTEMI and STEMI in 2011 and 2012, respectively. Uptake of new drugs into Figure 2 The number of patients with ACS receiving ticagrelor during hospitalization.
Contemporary use of ticagrelor clinical practice is known to be affected by multiple factors. Government subsidies that partly cover the cost of drugs in Sweden are likely to play a role. Scientific evidence is also important, and the publication of PLATO was without doubt essential for the success of ticagrelor. The associated change in ESC guidelines is likely to have played a role, although the existence of guidelines does not necessarily mean that recommendations are always followed. 18 We noted that patients discharged on ticagrelor constituted a subset of ACS cases with a more benign risk factor profile and a lower risk of bleeding. This may not be entirely unexpected as an obstacle to implementation of evidence-based therapies is the perceived greater complexity and co-morbidities of real-world patients than those enrolled in clinical trials. 19, 20 While clinicians may, therefore, be more inclined to use ticagrelor in cases with less co-morbidities and lower risk, we also did note that a high proportion of ticagrelor patients underwent PCI and that the use of ticagrelor was more common at hospitals with PCI capability. Interestingly, data from both a pre-specified subgroup analysis of PLATO, as well as from a post hoc study, have shown that patients who undergo PCI derive similar benefit to patients who do not. 21, 22 It is, therefore, incorrect to view ticagrelor as a drug that is especially suited for invasively managed patients. An alternative explanation for the tendency of PCI-capable hospitals to use ticagrelor may be that the dissemination of clinical management and prescription patterns follows professional networks that can predispose to local or regional variations in clinical practice. 23 The PLATO trial was designed to target a population at elevated risk: patients were required to have ACS and at least 1 cardiovascular risk factor to be eligible for inclusion. While patients discharged on ticagrelor in the present study were older than in PLATO (67 vs. 62 years) and a higher proportion had STEMI (46 vs. 38%), several other important risk factors were in fact less prevalent in the present population including diabetes, hypertension, past history of MI, and peripheral vascular disease. In keeping with this, we found significantly lower GRACE scores in patients discharged on ticagrelor, which indicates a lower risk of death in this subpopulation. Interestingly, the related P2Y12 inhibitor prasugrel has been shown to be more commonly used in patients at lower cardiovascular risk, 24 a phenomenon likely to relate both to a fear of bleeding complications and to the so-called risk-treatment paradox, which posits that clinicians are more likely to institute guideline-based therapy for ACS in low-risk patients. 25, 26 A recently published evaluation of ticagrelor prescription patterns in patients undergoing PCI in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium similarly demonstrated that the co-morbid state of patients prescribed ticagrelor was better than in those given clopidogrel, but worse than in those given prasugrel. 27 This illustrates a known limitation of randomized controlled trials (RCT), which is that the population receiving the drug in the real world is commonly not identical to the population studied in the RCT. 28 Future studies that evaluate outcomes with ticagrelor post-ACS in the real world are therefore awaited with interest. The present study showed that only 82.5% of patients were a priori intended for treatment with ticagrelor for 12 months at the time of discharge. Giving ticagrelor for ,12 months post-ACS is also at variance with ESC guidelines, which give a Class I recommendation to maintaining P2Y12 inhibition for 12 months. 4 It is noteworthy that the event curves of PLATO continued to diverge during the entire 12 months of follow-up. 1 While the physiological processes behind this long-term benefit of ticagrelor remain uncertain, recent trial data have demonstrated the efficacy of sustaining treatment well beyond the initial, unstable phase in patients with ACS. 29 As for the discrepancy between ticagrelor duration in our real-world patients vs. PLATO, one potential explanation may be that DAPT was deliberately stopped early owing to an elevated risk of bleeding. However, analysis of bleeding risk scores did not support this notion as the CRUSADE score was in fact lower in ticagrelor patients than others; the difference being statistically significant but numerically small and possibly of limited clinical significance. Alternatively, it is conceivable that ticagrelor was intended for ,12 months as a switch to clopidogrel was anticipated, for financial reasons or otherwise. 30 Data on the prescriptions filled
will be required to demonstrate how much ticagrelor was actually dispensed to patients, and outcome data are required in order to understand whether stopping ticagrelor prematurely post-ACS was associated with adverse outcomes. The aforementioned reports of P2Y12 prescription patterns have shown that prasugrel is given to a surprisingly high proportion of cases with relative or absolute contraindications. Sherwood et al. reported from the ACTION registry that prasugrel was given in 2% of patients aged ≥75 years, 5% of patients with body weight ≤60 kg, and 3% of patients with prior stroke. 24 Sandhu reported from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium that up to 10% of patients given prasugrel had a contraindication and that 28% did not even have an ACS. 31 In the case of ticagrelor, data are available in the aforementioned report by Karve et al., which found that 14% of patients treated with ticagrelor post-PCI did not have an ACS. As the study protocol for the present study only incorporated patients that met criteria for ACS, our ability to extrapolate findings to patients with non-ACS presentations or troponinnegative ACS is limited. Nonetheless, the present report extends the findings of Karve et al. by demonstrating that the intended treatment duration does differ from PLATO and that co-prescription with warfarin in fact occurs in a minority of patients. 27 
Limitations
This study does have a number of limitations. Firstly, only patients with an ACS were included, i.e. patients with stable angina were not included, although it is possible that ticagrelor may be used offlabel in such patients too. 28 Secondly, as discussed above, data were available to show intention to treat patients with ticagrelor postdischarge including treatment duration, but we did not have access to subsequent information on the amount of ticagrelor actually dispensed to patients.
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